Pursuant to the notice, the Extraordinary General Meeting of NeuroSearch A/S
was held today Monday 7 September 2009.

Ian Talmage was elected as a new Board member with immediate effect instead of
Gerard Van Odijk who retired from the Board today.

The suggested amendment to Article 5 of the Articles of Association following
which the Board of Directors during the period ending on 1 September 2014 is
authorised to increase the company's share capital in one or more issues of up
to a total nominal value of DKK 170,000,000 was agreed upon by the shareholders
with more than two third majority but could not be finally adopted as less than
half of the share capital was represented at the Extraordinary General Meeting.

A new Extraordinary General Meeting will therefore be convened for 18 September
2009 at 2 pm where the same amendment will be presented for final adoption.


Flemming Pedersen
CEO


Contact persons:
Flemming Pedersen, CEO, telephone: +45 2148 0118
Hanne Leth Hillman, Vice President, Director of Investor & Capital Market
Relations, telephone: +45 4017 5103



About NeuroSearch
NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on NASDAQ
OMX Copenhagen. The core business of the company covers the development of
novel pharmaceutical agents, based on a broad and well-established drug
discovery platform focusing on ion channels and central nervous system (CNS)
disorders. A substantial share of the activities is partner financed through
strategic alliances with Janssen Pharmaceutica, Eli Lilly and Company and
GlaxoSmithKline (GSK), and license collaboration with Abbott. The drug pipeline
comprises seven clinical (Phase I-III) development programmes:
Huntexil™ (pridopidine) for Huntington's disease (Phase III), tesofensine for
obesity (Phase III ready), ABT-894 for ADHD (Phase II) in partnership with
Abbott, ACR343 for schizophrenia (Phase II ready), ACR325 to treat dyskinesias
in Parkinson's disease (Phase Ib), ABT-560 for the treatment of cognitive
dysfunctions (Phase I) in collaboration with Abbott, NSD-788 for anxiety (Phase
I) and NSD-721 for social anxiety disorder (Phase I) in collaboration with GSK.
In addition, NeuroSearch has a broad portfolio of preclinical drug candidates
and holds equity interests in several biotech companies.

fonds.44-09 - afholdt ekstraordinær 07 09 2009 - uk - final.pdf